Teriparatide biosimilar - Pfenex

Drug Profile

Teriparatide biosimilar - Pfenex

Alternative Names: PF-708

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfenex
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoporosis

Most Recent Events

  • 09 Aug 2017 Pfenex announces intention to submit NDA to the US FDA for teriparatide biosimilar in the third quarter of 2018
  • 15 Mar 2017 Pfenex completes a bioequivalence trial in Osteoporosis (In volunteers)
  • 01 Dec 2016 Phase-III clinical trials in Osteoporosis in USA (SC) (NCT03002428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top